In this audio activity, Dr. Goldberg describes his approach to patients with idiopathic or clonal cytopenias of undetermined significance (ICUS and CCUS).

When to consider iron chelation therapy for a transplant-eligible patient

Mar 20th, 2018 3m 56s

Listen as Dr. Goldberg explains his approach to iron chelation therapy in patients who are, or may be within the next 5-10 years, eligible for transplant.

53-year-old woman presenting with severe fatigue and bruising

Mar 20th, 2018 3m 58s

Hematopathologist Dr. Khoury presents a case snapshot showing the complexities of diagnosing AML, describing the importance of morphology, flow cytometry, cytogenetics, and molecular diagnostics.

New subcategories of pancreatic cancer allow for a biomarker-driven approach to therapy

Jan 5th, 2018 4m

Dr. O'Reilly discusses the new subcategories of pancreatic cancer that have emerged, and which are laying the groundwork for a biomarker-driven approach to therapy.

What are the unique aspects of pancreas cancer that lead to the development of novel therapeutics?

Jan 5th, 2018 2m 40s

Dr. O'Reilly discusses the unique pathophysiology of pancreas cancer that must be considered in the development of novel therapeutics.

Predictors of response to lenalidomide in a non-del(5q) MDS patient

Jan 5th, 2018 3m 3s

Listen as Dr. Goldberg discusses, in just under two minutes, the predictors of response to lenalidomide in a non-del(5q) MDS patient.

What are the pros and cons of radiation therapy?

Dec 21st, 2017 2m 29s

Listen as Dr. Matasar discusses the pros and cons of radiation therapy, and who should be offered this therapy.

What defines high-quality survivorship care for patients treated for classical Hodgkin lymphoma?

Nov 30th, 2017 3m 1s

Listen as Dr. Matasar discusses survivorship care for patients who have been treated for classical Hodgkin lymphoma, including late effects of treatment.

Second primary malignancies associated with lenalidomide maintenance

Nov 30th, 2017 2m 53s

Dr. Jacob Laubach discusses second primary malignancies associated with lenalidomide maintenance in the transplant and post-transplant setting.

Impact of consolidation therapy in patients post-transplant

Nov 30th, 2017 3m 9s

Dr. Laubach discusses the impact of consolidation therapy in patients post-transplant, referencing results of the CTN StaMINA trial.

Bortezomib as an alternate strategy for maintenance therapy.

Oct 23rd, 2017 2m 32s

Dr. Jacob Laubach discusses bortezomib as an alternate strategy to lenalidomide for maintenance therapy in patients with multiple myeloma.

What may be the future role for brentuximab vedotin in newly diagnosed Hodgkin lymphoma?

Oct 23rd, 2017 2m 35s

Listen as Dr. Matasar discusses the future role of brentuximab vedotin in patients with newly diagnosed classical Hodgkin lymphoma.

Has MRD testing become a standard of care in multiple myeloma?

Oct 23rd, 2017 3m 22s

Dr. Ruben Niesvizky discusses MRD testing and how it has become a standard of care in multiple myeloma, as well as future directions in MRD testing that will improve outcomes in these patients.

The Precision Promise [SM] Initiative: What is it designed to achieve?

Sep 27th, 2017 4m 32s

Dr. O'Reilly provides an insightful overview of how the emerging use of precision medicine and the Precision Promise [SM] initiative will impact the new drug approval process in pancreatic cancer.

Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study

Sep 27th, 2017 8m 26s

Dr. Eytan Stein provides a brief update on phase 1 arms of a trial studying the effectiveness of enasidenib in patients with relapsed and refractory AML and an IDH2 mutation.

What are the optimal imaging methods to determine extent of bone disease in newly diagnosed MM?

Sep 27th, 2017 3m 18s

Dr. Ruben Niesvizky discusses newer approaches for imaging in patients who have multiple myeloma with bone disease, including the benefits of combining modalities such MRI and PET scan.

The standard of care for patients receiving lenalidomide or thalidomide who are at high risk for VTE

Sep 27th, 2017 3m 36s

Dr. Ruben Niesvizky discusses clinical approaches to managing the risk of developing VTE in myeloma patients receiving immunomodulating agents such as lenalidomide or thalidomide.

How do I dose daratumumab, lenalidomide and dexamethasone in the combination regimen?

Sep 27th, 2017 1m 59s

In under two minutes, Dr. Carol Ann Huff will discuss how to dose daratumumab in conjunction with lenalidomide and dexamethasone in patients with multiple myeloma.

Is there a connection between pancreatic cancer and new-onset diabetes?

Aug 18th, 2017 8m 26s

Dr. Anil Rustgi discusses a clinical prediction model to assess risk for pancreatic cancer among patients with new-onset diabetes.

CPX versus 7 and 3 conventional chemotherapy in older adults with AML

Aug 18th, 2017 3m 16s

Dr. Stuart Goldberg briefly summarizes updates on CPX-351, a liposomal form of cytarabine and daunorubicin that allows for office infusion vs. standard consolidation requiring hospitalization.